Objective: Failure to properly dispose of glucose in response to insulin is a serious health problem, occurring during obesity and is associated with type 2 diabetes development. Insulin-stimulated glucose uptake is facilitated by the translocation and plasma membrane fusion of vesicles containing glucose transporter 4 (GLUT4), the rate-limiting step of post-prandial glucose disposal. Methods: We analyzed the role of Tusc5 in the regulation of insulin-stimulated Glut4-mediated glucose uptake in vitro and in vivo. Furthermore, we measured Tusc5 expression in two patient cohorts. Results: Herein, we report that TUSC5 controls insulin-stimulated glucose uptake in adipocytes, in vitro and in vivo. TUSC5 facilitates the proper recycling of GLUT4 and other key trafficking proteins during prolonged insulin stimulation, thereby enabling proper protein localization and complete vesicle formation, processes that ultimately enable insulin-stimulated glucose uptake. Tusc5 knockout mice exhibit impaired glucose disposal and TUSC5 expression is predictive of glucose tolerance in obese individuals, independent of body weight. Furthermore, we show that TUSC5 is a PPARg target and in its absence the anti-diabetic effects of TZDs are significantly blunted. Conclusions: Collectively, these findings establish TUSC5 as an adipose tissue-specific protein that enables proper protein recycling, linking the ubiquitous vesicle traffic machinery with tissue-specific insulin-mediated glucose uptake into adipose tissue and the maintenance of a healthy metabolic phenotype in mice and humans.
INTRODUCTION
In healthy individuals post-prandial glucose is quickly cleared from the circulation into muscle and adipose tissue in response to insulin stimulation by ATP-independent facilitative diffusion through glucose transporter 4 (GLUT4) [1] . During insulin resistance, a common comorbidity of obesity and a hallmark of type 2 diabetes, GLUT4 translocation to the plasma membrane is impaired [2, 3] . In both muscle and adipocyte-specific GLUT4 knockout mice, glucose homeostasis is impaired and insulin resistance develops [4, 5] . These same diabetic symptoms are also present in heterozygous GLUT4 mice, despite the fact that these mice do not become obese [6] . In accordance, global and tissue-specific GLUT4 over-expression mouse models exhibit improved insulin sensitivity and glucose homeostasis, even in obese and diabetic mice [7e10] . Collectively, these findings demonstrate GLUT4's importance in the maintenance of a healthy metabolic phenotype.
Functional regulation of GLUT4 is accomplished via control of its cellular trafficking, a process that is driven by a variety of proteins [11e13] . These proteins ensure proper vesicle fusion (e.g. VAMPs) [14, 15] , confer vesicle motility and directionality (e.g. Rabs, IRAP) [11, 16] , participate in protein recycling (e.g. STX6) [17, 18] and act as vesicle tethers (e.g. TUG) [19, 20] . Several of these proteins co-localize with GLUT4 to specialized vesicles termed GLUT4 storage vesicles (GSVs) [21, 22] that act as the main intracellular insulin-responsive GLUT4 reservoir [23] . Interestingly, each of the proteins with a known role in GLUT4 trafficking also participates in similar vesicle traffic systems in other tissues [24e26] ; currently no adipose tissuespecific protein link exists between the specific insulin-mediated function of GLUT4 and the ubiquitous trafficking machinery it exploits [22] . Protein recycling is a particularly vital step to the long-term function of GLUT4 [27] . GLUT4 is cleared from the plasma membrane by endocytosis after the cessation of insulin stimulation or during a prolonged 1 insulin stimulus [28e31] . Following internalization, GLUT4 is enriched in endosomal compartments containing proteins that actively participate in protein recycling, such as syntaxins 6 and 16 [17, 18] and VAMP3 [32] , and cargo proteins, such as the transferrin receptor (TfR) [33, 34] . It is through this endosomal recycling pathway that GLUT4 is either shuttled back to the plasma membrane, in the case of prolonged insulin stimulation, or, if insulin stimulation has ceased, sequestered back in GSVs [11,12,35e37] . Tumor suppressor candidate 5 (TUSC5), is a protein abundantly expressed in white [38] and brown adipose tissue [39] and Tusc5 mRNA expression increases during adipogenesis [39, 40] . Evidence exists that TUSC5 is a PPARg target gene as PPARg has been shown to bind to the promoter region of TUSC5 [41] and Tusc5 mRNA expression increases in adipocytes treated with the PPARg agonist GW1929 [40] . Although these data collectively suggest that TUSC5 may serve a function in mature adipocytes, to date, the mechanism of action, physiological consequences and the importance of TUSC5 in the pathogenesis of obesity remain unknown.
MATERIAL AND METHODS

Materials
All chemicals were purchased from SigmaeAldrich unless specified otherwise.
Animals
C57Bl/6 mice were housed in a pathogen-free animal facility on a 12-h/12-h light/dark cycle with free access to food and water.
Plasmids
For lentivirus production Mission shRNA (SigmaeAldrich) against TUSC5 was used. For adenovirus production shRNAs against TUSC5 were designed (http://rnaidesigner.invitrogen.com/rnaiexpress/), cloned into pENTR-U6 and recombined into pAd-BLOCK-iT-DEST (Invitrogen). VAMP2 cDNA amplified from murine adipocyte cDNA was cloned into pCDNA3.1/V5-His. Primer/shRNA sequences are available upon request.
Western blot analysis
Whole cell lysates were prepared as previously described [42] . For western blot analysis (and other experiments) the following antibodies were used: TUSC5 (Santa Cruz Biotechnology, SC-292062, 1:1000), GLUT4 (Cell Signaling, #2213, 1:1000; Millipore, 07-1404, 1:1000), Akt (Cell Signaling, #9272, 1:1000), phospho-Akt (Cell Signaling, #4056, 1:1000), Sortilin (BD Bioscience, #612100, 1:1000), V5 (Invitrogen, #46-07-05, 1:5000), Cellugyrin (Santa Cruz Biotechnology, SC-68935), c-Myc (Sigma Aldrich, C3956) and gTubulin (SigmaeAldrich, T6557, 1:6000). Western blot quantification was done using ImageJ software.
2.5. Cell culture 3T3-L1 cells and immortalized brown preadipocytes were seeded onto collagen-coated plates and grown in high-glucose DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (all Invitrogen) prior to differentiation. Three days postconfluent 3T3-L1 cells were treated with induction cocktail (1 mg/ml insulin, 1 mM dexamethasone and 115 mg/ml isobutyl-methylxanthine) for 2 days followed by insulin media (1 mg/ml insulin) for 2 days and DMEM for 3 days. For rosiglitazone treatment cells were stimulated with 1 mM rosiglitazone in DMEM and media was changed every 24 h.
Immortalized brown preadipocytes were induced at day of confluence with 117 ng/ml insulin, 1 mM dexamethasone, 115 mg/ml isobutylmethylxanthine, 125 mM indomethacin, 1 nM Rosiglitazone and 1 nM T3 for 2 days and subsequently maintained in insulin (117 ng/ mL)/T3 (1 nM) media for differentiation into mature adipocytes. L6 and L6-Glut4myc cells were obtained from the Klip lab (The Hosptial for Sick Children, Toronto, CA) and cultured in low glucose a-MEM (Invitrogen) enriched with 10% FBS and 1% penicillin/streptomycin. Formation of myotubes was stimulated by decreasing the FBS concentration to 2% for the entire duration of differentiation.
2.6. Real-time PCR mRNA was isolated and transcribed into cDNA using the Multi-MACS cDNA kit (Miltenyi). Expression levels of mRNA were assessed by real-time PCR using SybrGreen (Invitrogen) according to the manufacturer's protocol. Expression was normalized to GAPDH or 36B4. Primer sequences are available upon request.
Viral infection
Lentiviral stocks were prepared as previously described [42] . For lipid droplet assays 3T3-L1 cells were infected for 24 h with virus containing media supplemented with polybrene (8 mg/ml) 3 days before adipogenic induction. Adenovirus production was done in HEK293A cells with pAd-TUSC5-shRNA crude lysate. Adenovirus was purified using a column system (Virapur). For mature adipocyte experiments, adenoviral infection was done 2 days after 3T3-L1 adipogenic induction or at d8 of differentiation in Opti-MEM media (Invitrogen) supplemented with 1.2% poly-lysine for 24 h. All mature adipocyte experiments were performed 5e6 days after adenovirus infection. Likewise, L6 and L6-Glut4myc cells were virus infected at d3 of differentiation and experiments performed at d8.
Epididymal fat pad injections
Adenovirus was injected (40 ml, 1 Â 10 10 PFU/ml per fat pad) into the epididymal fat pad of ten-weeks old C57Bl/6 mice [43] . To place the injections exclusively into the epididymal fat pad, anaesthetized mice were fixed in a dorsal position and the pads were exposed under sterile conditions. After midline laparotomy (incision length 0.5e1 cm ending approximately 1 cm rostral to the urethral orifice), both fat pads were carefully pulled out of the intra-abdominal perigonadal area. Adenovirus was slowly injected with a 30G needle (BD Diabetes), which penetrated the distal end of the depot first and was then pushed forward to the proximal end. After careful repositioning of the intraabdominal perigonadal area, the abdominal wall was sutured in two layers (the peritoneum parietale, followed by the skin) with 2e3 single stitches of absorbable suturing material (Vicryl 6-0, Ethicon). Anaesthesia was performed by isoflurane (induction: 4e5%, maintenance: 1e3%) and for analgesia Meloxicam (5 mg/kg, sc) was administered 30 min prior to surgery and post-operatively via drinking water (1.7 mg/ ml) for 3e4 days. Six days after injection the mice were fasted for 16 h prior to experiments.
Glucose uptake
In vitro glucose uptake was performed on 3T3-L1 adipocytes 5 days after adenoviral knockdown of TUSC5. Briefly, cells were incubated at 37 C in KrebseRinger buffer containing insulin, 2 mM glucose and 14 C-deoxyglucose (200 cpm/ml). After 2 h cells were washed twice with ice cold PBS and lysed by one freeze thaw cycle in 2 M NaOH. Lysates were mixed with 3 ml scintillation cocktail and intracellular radioactivity was quantified in disintegrations per minute (dpm). In vivo glucose uptake was performed in C57Bl/6 mice six days after adenoviral injection into epididymal adipose tissue. In short, mice were fasted overnight (16 h) prior to receiving a tail vein injection of 100 ml 14 C-deoxyglucose (250,000 cpm/ml) and 0.3 ml 3 H-mannitol (2,600,000 cpm/ml) with insulin (0.5 IU/kg) or 0.9% NaCl solution. Mice were sacrificed by cervical dislocation after 30 min and eWAT depots were removed, weighed and dissolved for 1 h in 1 M NaOH at 60 C. To calculate 2-deoxyglucose-6-phosphate synthesis lysate was neutralized with an equal volume of 1 M HCl.
14 C-deoxyglucose was isolated from lysates by mixing 200 ml of lysate with 500 ml of 0.3 M ZnSO 4 and 500 ml of 0.3 M Ba(OH) 2 . A 14 C-deoxyglucose and 14 C-deoxyglucose-6-phosphate mix was isolated by mixing 200 ml lysate with 1 ml of 6% perchloric acid. Both samples were vortexed and centrifuged for 2 min and 13,000g. 800 ml of each supernatant was mixed with 3 ml scintillation cocktail total radioactivity was quantified in dpm and 2-deoxyglucose-6-phosphate was calculated.
2.10. Adipocyte differentiation analysis Differentiated cells were fixed with 4% formaldehyde prior to staining with Hoechst (nuclei), BODIPY (lipid droplets) and Syto60 (cytosol) (Invitrogen). Sixteen pictures were taken per well with an automatic imaging system (Operetta) and analyzed for lipid droplet sizes using Cell Profiler software [42, 43] .
2.11. Tissue whole mount staining Prior to eWAT isolation C57Bl/6 mice were perfused with 0.9% NaCl solution. eWAT was isolated and cut into 2e4 mm pieces and fixed with 4% paraformaldehyde. Tissue sections were permeabilized with PBS-T (PBS with 0.5% Triton-X) followed by blocking for 2 h in blocking buffer (PBS, 5% donkey serum, 0.05% sodium azide, 1% BSA, 0.1% Triton-X) and overnight incubation at 4 C with primary antibodies (TUSC5, GLUT4, 1:750). The following day sections were washed (4 times, 20 min) with PBS-T and incubated at room temperature with secondary antibody (a-rabbit Alexa488, A21206, Invitrogen; a-mouse Alexa 568, A11031, Invitrogen; both 1:300) for 2 h.
Sections were washed (4 times, 20 min each) with PBS-T and mounted with Vectashield (Reactolab) prior to confocal imaging (Leica SP2-AOBS).
Immunofluorescence
Insulin-stimulated Glut4/Vamp3 localization was visualized as previously described [44] . Briefly, mature (d12) 3T3-L1 adipocytes were fasted in serum free DMEM for three hours and stimulated with 100 nM insulin (for indicated times) and washed (all washes were 6 times, 5 min, PBS 2.14. Mass spectrometry After peptide elution, samples were reduced and alkylated with 5 mM TCEP (tris(2-carboxyethyl)phosphine) and 10 mM Iodoacetamide.
Peptides were cleaned with 3e30 mg UltraMicroSpin columns (The Nest Group), dried in a speed-vac and resolubilized in 0.1% formic acid.
For reversed-phase chromatography, a high-performance liquid chromatography (HPLC) column (75-mm inner diameter, New Objective) that was packed in-house with a 10-cm stationary phase (Magic C18AQ, 200 E, 3 mm, Michrom Bioresources) was used which was connected to either a nano-flow HPLC (nanoLC-Ultra 1D plus, Eksigent) and an autosampler (nanoLC AS-2, Eksigent) or a Proxeon easy-nLC system (Odense, Denmark). The HPLC was coupled via a nanoelectrospray ion source (Thermo Scientific) to a LTQ-Orbitrap XL mass spectrometer (Thermo Scientific). After loading the peptides on the column with 95% buffer A (98% H 2 O, 2% acetonitrile, 0.1% formic acid), they were eluted at flow rate of 300 nl/min over a 60 min linear gradient from 5 to 35% buffer B (2% H 2 O, 98% acetonitrile, 0.1% formic acid). Mass spectra were acquired in a data-dependent acquisition mode with one cycle consisting of one MS1 scan followed by 3 or 5 MS/MS scans. Precursor ions were monitored in the mass range of 350e1650 m/z by a high resolution MS1 scan acquired in the Orbitrap (60,000 FWHM, target value 10 6 ). For MS/MS scans, precursor ions were fragmented by collision induced dissociation in the ion trap (minimum signal threshold 150, target value 10 4 , isolation width 2 m/z). Unassigned charged states, as well as singly charged ions, were excluded from fragmentation and the dynamic exclusion was set to 10 s. ReadW (version 4.3.1) was used to convert raw data into the open mzXML format. The mzXML files were searched with SORCERER (Version 3.5) against the mouse UniProtKB/Swiss-Prot protein databases (release 2012_07). Search parameters for peptide-spectrum matching contained a peptide mass tolerance of 50 ppm, a minimum of one tryptic terminus, a maximum of one internal trypsin cleavage sites and cysteine carbamidomethylation (þ57.021 Da) as a static amino acid modification. For probability scoring of peptides and proteins the Trans-Proteomic Pipeline (Version 4.0.2) was used including PeptideProphet and ProteinProphet, and protein identifications were filtered to a false-discovery rate of 1%. For MS1 based label-free quantification of the identified peptides, MS1 ions signals corresponding to peptide features were extracted with the SuperHirn (Version 03) software. After intensity normalization, peptide signal intensities belonging to the same protein were summarized followed by statistical analysis of the data.
Cell fractionation assays
Fractionation of 3T3-L1 adipocytes or primary adipose tissue into plasma membrane and low-density microsome (LDM) fractions was performed as previously described [45] . For further LDM fractionation the fraction was resuspended in 50 ml TES buffer and layered on top of phosphate buffer (16 mM Na 2 HPO 4 , 4 mM NaH 2 PO 4 , 50% sucrose (w/ v)) and centrifuged at 150,000g for 30 min. Fractions were collected in 100 ml aliquots.
2.16. Plasma membrane lawn assay Differentiated 3T3-L1 cells (Lab-Tek chamber slides) were serum starved for 2 h prior to insulin treatment. Cells were sequentially washed in PBS, 1 mg/ml of poly-lysine in buffer A (70 mM KCl, 30 mM HEPES, 5 mM MgCl 2 , 3 mM EGTA, pH 7.5) for 30 s, two washes in hypotonic buffer A (1/3 buffer A, 2/3 H 2 O) and sonicated (amplitude ¼ 1, 2 s) in buffer A. Lawns were washed 3 times in PBS and stained for plasma membrane with CellMask (Invitrogen) at 5 mg/ ml according to manufacturer's protocol. Lawns were fixed (4% formaldehyde), blocked (5% goat serum), incubated with GLUT4 antibody (1:200, Millipore) followed by Alexa488 secondary antibody (1:300, Invitrogen). Both antibodies incubated for 1 h at room temperature. Three PBS washes were performed between steps. Lawns were mounted with Vectashield for imaging (Leica SP2-AOBS).
2.17. GLUT4-myc assays GLUT4-myc plasma membrane integration assays were done as previously described [46, 47] ; however, the re-warming endocytosis step was omitted. 3T3-L1 adipocytes were cultured overexpressing exofacially myc-tagged GLUT4, with or without a TUSC5 knockdown. Cells were serum-starved (2 h) and subsequently stimulated with insulin (15 min) in DMEM. All washes and treatments were done at 4 C in PBS þ (PBS, 1 mM CaCl 2 , 1 mM MgCl 2 ). Non-permeabilized cells were blocked (5% goat serum, 20 min), labeled with myc antibody (Sigmae Aldrich, 1:250 in 3% goat serum, 1 h) and fixed in 4% paraformaldehyde. Excess fixative was quenched in 100 mM glycine. GLUT4-myc bound antibody was detected with HRP-conjugated secondary antibody (a-rabbit HRP, Jackson Immune Research, #111-035-144, 1:1000 in 3% goat serum, 1 h) followed by HRP detection by OPD assay as previously described [47] . Total GLUT4-myc expression was checked in permeabilized cells (0.1% Triton-X in PBS þ ) (Supplementary Figure 4) . A modified protocol was used to assess surface Glut4myc levels in L6 and L6-Glut4myc cells overexpressing Tusc5. Insulin stimulation was terminated with cold PBS and cells subsequently fixed in 4% formaldehyde for 10 min at 4 C. The fixative was quenched as above and cells blocked with 5% BSA in PBS for 40 min at RT. Primary (c-myc A-14, sc-789, 1:200) and secondary antibody incubations were done for 1 h at 37 C, each followed by thoroughly washing with PBS/ 0.05% Tween-20 (3Â) and PBS þ (3Â). ABTS was used as substrate for HRP, the reaction stopped with 1% SDS and the absorbance was measured at 405 nm. Cells for immunofluorescence assays were cultured on chamber slides and subjected to the same staining protocol (c-Myc antibody at 1:150, 5% goat serum) up to the fixation step.
Subsequently, cells were stained with a-rabbit Alexa488 (Invitrogen, 1:300, 5% goat serum, 1 h) and mounted in Vectashield with DAPI for confocal imaging (Leica SP2-AOBS). ) insulin (Actrapid 100 IU/ml, Novo Nordisk, Denmark) infusion was used to achieve hyperinsulinemia. Blood glucose was measured in 5-minute intervals. Euglycemia was maintained using variable infusion rate of 20% glucose. The whole body insulin sensitivity index (M-value) was calculated from the steady state plasma glucose infusion rate required to maintain euglycemia, expressed per kg body weight per minute during the last 60 min of the 2.5 h clamp.
Bioethics
All animal studies were approved by the Canton of Zurich Veterinary Office. The human work on obese subjects was carried out at the University Hospital of Heidelberg, with approval from the ethics committee of the hospital. Informed consent was obtained from all patients participating in this study.
Human studies ethics statement
All studies were approved by the Ethics Committee of the University Hospital Bratislava, Comenius University Bratislava and the university hospital Heidelberg and are conforming to the ethical guidelines of the 2000 Helsinki declaration. All participants provided witnessed written informed consent prior entering the study.
Statistical analysis
Results are given as mean AE standard error. Statistical analyses were performed using a two-tailed Student's t-test. Linear regression was calculated using Graph Pad Prism.
RESULTS
3.1. TUSC5 co-localizes with GLUT4 and is required for insulinstimulated glucose uptake We initially identified Tusc5 as a gene highly expressed in inguinal white adipose tissue (iWAT), epididymal white adipose tissue (eWAT) and brown adipose tissue (BAT) with a low degree of expression in skeletal muscle and heart ( Figure 1A) . As Tusc5 mRNA expression is specific to adipose tissue we first analyzed its role in lipid storage and release. When TUSC5 was ablated in adipocytes (Supplementary Figure 1A and B) basal and insulin-stimulated repression of lipolysis was unaltered (Supplementary Figure 2) . Interestingly, TUSC5 knockdown during adipocyte differentiation resulted in smaller lipid droplets (Supplementary Figure 3A and B) . As glucose is a key substrate for de novo lipogenesis, we investigated whether TUSC5 modulates glucose uptake. Indeed we found that insulin-stimulated glucose uptake in adipocytes was significantly blunted during a TUSC5 knockdown ( Figure 1D ), while basal glucose uptake was unaffected ( Figure 1D ). To confirm these effects in vivo, eWAT of wild-type C57Bl/6 mice was injected with adenovirus containing a shRNA targeting TUSC5 (right depot) or a scramble control (left depot), resulting in an approximate 50% ablation of TUSC5 after six days (Supplementary Figure 4A and B) . Mice were subsequently tail vein injected with 2-deoxyglucose (in the presence or absence of insulin) and 2-deoxyglucose-6-phosphate (2DOG6P) was precipitated and quantified. Interestingly, we observed a significant difference in glucose uptake between paired depots (i.e. shRNA-eWAT and control-eWAT from the same mouse) only in the TUSC5-ablated eWAT of insulin-stimulated mice ( Figure 1E ), demonstrating TUSC5's importance in insulin-mediated glucose uptake, in vivo. Expression levels of GLUT4 and AKT, as well as phosphorylation of AKT (pAKT), were not affected by TUSC5 knockdown, in vitro or in vivo (Supplementary Figure 5 , data not shown), demonstrating that post-receptor insulin signaling is not dependent on TUSC5. We next examined the cellular localization of TUSC5 by whole mount staining of eWAT. As shown in Figure 2A , endogenous TUSC5 colocalizes with GLUT4 at the plasma membrane (PM). Since the intracellular area of adipocytes in vivo is largely composed of lipids we next examined TUSC5 localization in 3T3-L1 adipocytes. Prior to insulin stimulation TUSC5 is present both intracellulary and at the PM ( Figure 2B ). Upon insulin stimulation, TUSC5 translocates to the PM, similar to GSVs. Cell fractionation assays confirmed the observed shift of TUSC5 to the PM from the low-density microsome (LDM) vesicle fraction during insulin stimulation ( Figure 2C ). Further fractionation of the LDM fraction from adipocytes showed that TUSC5 localizes to vesicles of the same density as those containing bona fide GSV proteins such as GLUT4 and sortilin (Supplementary Figure 6) . Of note is the fact that Tusc5, in contrast to sortilin and other markers (Figure 1AeC ), is only highly expressed in adipose tissue, suggesting that TUSC5 might be the tissue-specific factor connecting GLUT4 with the ubiquitous trafficking machinery.
TUSC5 interacts with GLUT4 and facilitates its membrane fusion
Based upon these observations, we hypothesized that TUSC5 enables vesicle trafficking and/or function. To elucidate its mode of action, we precipitated endogenous TUSC5 and GLUT4 from adipocytes and analyzed co-precipitants by mass spectrometry (MS) using MS1 based label-free quantification ( Figure 3A and B and Supplementary Table 1 ). We could show that endogenous TUSC5 co-precipitates GLUT4 in both a basal and insulin-stimulated state ( Figure 3A and B) , and vice versa ( Figure 4B ). Interestingly, a host of proteins known to participate in GLUT4 or GSV trafficking (e.g. IRAP, STX6) [11, 15, 23] were observed to co-precipitate with both TUSC5 and GLUT4 ( Figure 3B ). In particular, proteins known to participate in trafficking at the recycling endosome/ trans-golgi network (TGN) interface, such as STX16 and VAMP3 [15, 18] , strongly associate with both proteins ( Figure 3B ). These data confirm that TUSC5 interacts with the GLUT4 trafficking machinery at various stages of its trafficking cycle.
Since GLUT4 trafficking to the PM is a crucial step for glucose uptake [13] , we next investigated GLUT4 exocytosis in response to insulin in the absence of TUSC5. We could show by plasma membrane sheet assay that depletion of TUSC5 did not inhibit insulin-stimulated GLUT4 translocation to the PM ( Figure 3C ). In fact, in cell fractionation assays, TUSC5 ablation led to an increase of GLUT4 at the PM in a basal state, although no additional increase in GLUT4 presence at the PM was observed after prolonged insulin stimulation ( Figure 3D ). Thus, TUSC5 ablation does not inhibit glucose uptake by reducing the ability of GLUT4 to traffic to the PM. As insulin-stimulated GLUT4 translocation remains intact during a TUSC5 knockdown, we investigated GLUT4 membrane fusion using a previously described exofacially myc-tagged GLUT4 construct (GLUT4-myc) [13, 46] . Under control conditions transgenic GLUT4-myc is able to fuse with the plasma membrane following insulin stimulation ( Figure 3E , left panels) but extracellular myc was not detectable after TUSC5 ablation ( Figure 3E, right panels) . Similarly, spectrophotometric quantification of extracellular myc-tag exposure confirmed insulininduced GLUT4-myc membrane fusion inhibition in the absence of TUSC5 ( Figure 3F ). In all conditions, GLUT4-myc expression remained constant (Supplementary Figure 7) . These results demonstrate that the impaired insulin-stimulated glucose uptake observed upon TUSC5 ablation results from a blunting of the GLUT4 fusion mechanism at the PM.
TUSC5 is necessary for proper GLUT4 recycling after insulin stimulation
Based upon our data we hypothesized that TUSC5 participates in GLUT4 recycling after insulin stimulation. To investigate, we performed immunoprecipitation (IP) assays targeting cellugyrin (CG), a protein that marks a distinct non-insulin-responsive GLUT4 vesicle population that is thought to comprise a portion of the endosomal recycling system [49, 50] (Supplementary Figure 8) . In control cells, IP of CG strongly coprecipitates GLUT4, however this association is severely diminished upon TUSC5 knockdown ( Figure 4A ). These findings suggest that TUSC5 is a key protein that ensures GLUT4 is able to properly transit through the recycling endosomes. Since TUSC5 ablation perturbs GLUT4 localization, we hypothesized that the observed glucose uptake phenotype is driven by a reduced association of GLUT4 with key parts of its trafficking machinery. Therefore, we analyzed endogenous GLUT4 co-precipitants by MS in the presence or absence of TUSC5 ( Figure 4B ). Among others, we identified 10 GLUT4 co-precipitants known to participate in trafficking and analyzed their relative abundances based on their MS1 intensities ( Figure 4C ). After normalization to GLUT4's average MS1 intensity three proteins, namely IRAP, STX12 and a shared VAMP2/3 peptide, showed a significantly reduced association with GLUT4 in the absence of TUSC5. Further, a reduced association of VAMP2 with GLUT4 on GSVs was confirmed in fractionation assays during a TUSC5 knockdown (Supplementary Figure 9) . To substantiate this, we further investigated the role of TUSC5 in protein recycling. We could show that under control conditions, both VAMP3, an intracellular vesicle fusion protein, and GLUT4 exhibit a predominantly perinuclear localization in a basal state (0 min) and disperse to the plasma membrane after insulin stimulation (15 min) ( Figure 4D, E and F) . Furthermore, we could show that this initial response is not affected by the knockdown of TUSC5 ( Figure 4D, E and F) . Interestingly, however, after the engagement of protein recycling during prolonged insulin stimulation (60 and 90 min) only cells expressing TUSC5 still showed a strong membrane staining for GLUT4 and VAMP3 indicating an ability to properly recycle to the PM, while TUSC5 ablation resulted in aberrant localization of both proteins throughout the intracellular compartment. Since muscle cells do not express TUSC5, we employed this model to further validate our hypothesis. Therefore, we used L6 cells stably transfected with myc-tagged GLUT4 in the presence or absence of adenoviral mediated TUSC5 overexpression and measured GLUT4 membrane fusion in response to insulin in a time dependent manner. As shown in Figure 4G we observed no changes in basal or insulinstimulated GLUT4 membrane fusion after 15 min. However, similar to our results in adipocytes, we observed sustained GLUT4 membrane fusion in cells overexpressing TUSC5 beyond 30 min of insulin stimulation, suggesting that muscle cells, which do not express TUSC5 has different dynamics of glucose uptake compared to TUSC5 expressing adipocytes.
Collectively, these findings demonstrate that TUSC5 is not required for GLUT4 membrane fusion upon an initial insulin stimulus, but rather is necessary for proper protein recycling during prolonged insulin stimulation, a key process in sustained GLUT4 membrane presence and insulin-stimulated glucose uptake. 
TUSC5 ablation leads to hyperglycemia and insulin resistance
To investigate the role of TUSC5 in the development of the metabolic syndrome global Tusc5 knockout mice were generated. As depicted in Figure 5A , primary adipocytes derived from iWAT, eWAT and BAT from Tusc5 knockout mice showed a significantly reduced glucose uptake in response to an insulin stimulus, similar to our cell culture observations, suggesting that TUSC5 might have a function in metabolic homeostasis, in vivo. Therefore, to further characterize the role of TUSC5 in metabolic control, Tusc5 knockout mice were placed on high-fat diet (HFD) along with wild-type littermates. Tusc5 knockout mice showed complete ablation of TUSC5 expression in iWAT, eWAT and BAT (Supplementary Figure 10) while expression of GLUT4 and other key proteins remained unaltered. On chow diet Tusc5 knockout mice did not differ from wild-type littermates with respect to weight and glucose clearance (Supplementary Figure 11, data not shown) . However, when challenged with a HFD, Tusc5 knockout mice exhibited a trend towards increased weight gain ( Figure 5B ). The fat pad weights and total body adiposity, however, did not differ significantly between the two groups (data not shown). Interestingly, Tusc5 knockout mice exhibited significantly elevated blood insulin ( Figure 5C ) and glucose levels ( Figure 5D ). In line with this, Tusc5 knockout mice developed insulin resistance as measured by IPGTT and ITT ( Figure 5E and F) . Taken together, these data demonstrate that TUSC5 is important for glucose disposal and that absence of TUSC5 leads to reduced glucose clearance and the development of insulin resistance.
3.5. TUSC5 is a PPARg target gene conferring the promotion of glucose disposal by PPARg activators As TUSC5 is a potential PPARg target [41] and its expression during 3T3-L1 adipocyte differentiation increases dramatically 1e2 days after Figure 12A and B) , we next investigated whether TUSC5 is a bona fide PPARg target gene. To this end, TUSC5 protein levels were examined in mature adipocytes treated with the PPARg agonist rosiglitazone. TUSC5 protein levels increased during rosiglitazone treatment, peaking at 36e48 h ( Figure 6A ). Conversely, TUSC5 protein levels were diminished differentiated brown adipocytes when PPARg was ablated by siRNA mediated knockdown ( Figure 6B ). Based on these cell culture findings, we next investigated if TUSC5 is a PPARg target in vivo. C57Bl/6 mice were treated with rosiglitazone or vehicle orally for 2 weeks and TUSC5 protein levels were examined in iWAT ( Figure 6C and D) . Rosiglitazone-treated mice showed an 8-fold increase in TUSC5 levels ( Figure 6C and D) , similar to the increase observed for aP2 and LPL, two known PPARg target genes. Based upon these findings, we hypothesized that TUSC5 may confer some of the anti-diabetic effects of PPARg agonists used in the treatment of type 2 diabetes. To investigate this, Tusc5 knockout mice and wild-type littermates were placed on a high-fat diet (HFD) to induce insulin resistance, at which time the mice were treated orally with rosiglitazone for two weeks. Rosiglitazone treatment significantly reduced both fasting blood glucose (33.3%) and fasting insulin levels (75%) in wild-type mice ( Figure 6E and F), but this effect was significantly blunted in Tusc5 knockout mice (19% reduction in blood glucose and 55% reduction in blood insulin levels). To substantiate our data, we isolated primary white and brown adipocytes from Tusc5 knockout and wild-type mice and treated those cells with rosiglitazone. As shown in Figure 6G we observed improved insulin-mediated glucose uptake in cells isolated from wild-type mice treated with rosiglitazone, an effect that was completely abolished in Tusc5 knockout mice ( Figure 6G ). Together, these data demonstrate that TUSC5 is a PPARg target protein that confers some of the beneficial effects of PPARg activators in the treatment of insulin resistance.
3.6. Tusc5 expression correlates with a healthy metabolic phenotype in humans Since TUSC5 is important for glucose disposal, in vitro and in vivo, we next investigated whether Tusc5 mRNA expression is predictive of the development of insulin resistance in patients. Our first cohort was comprised of lean and obese patients (BMI 20.6 to 38.6). The obese patients were further divided into insulin resistant/type 2 diabetic (according to 2014 ADA criteria of FPG > 7.0 mM and/or 2 h PG > 11.1 mM [51] ) and healthy obese patients. Across this entire cohort Tusc5 mRNA expression in scWAT showed an overall negative correlation with BMI ( Figure 7A ). However, this correlation significantly diminished when the cohort was stratified based upon their clinical diagnosis. Tusc5 mRNA expression was only significantly reduced in obese-diabetic patients when compared with lean or obese-healthy patients ( Figure 7B ), suggesting the correlation observed between Tusc5 mRNA expression and BMI ( Figure 7A ) is driven largely by the pathogenesis of type 2 diabetes rather than obesity alone. Supporting this idea is the fact that across the entire cohort Tusc5 mRNA expression strongly correlates with reduced fasting glucose levels ( Figure 7C ) and the M-index of insulin resistance as measured by clamp ( Figure 7D ). To substantiate our hypothesis, we next investigated Tusc5 mRNA expression in scWAT of a second cohort of exclusively obese individuals (BMIs ¼ 33.6 to 63.7) with varying degrees of insulin sensitivity [52e54] . In this cohort we did not observe a correlation between Tusc5 mRNA expression in scWAT and BMI (Supplementary Figure 13) . However, in agreement with our first patient cohort, Tusc5 mRNA expression significantly correlated with increased glucose tolerance ( Figure 7E ) and lower fasting insulin levels ( Figure 7F) . Collectively, these data show that in patients, Tusc5 mRNA expression is strongly associated with a healthy metabolic phenotype and that this association is largely independent of BMI.
DISCUSSION
Although the role of adipose tissue in glucose disposal and the maintenance of metabolic health are well established, many factors that promote glucose clearance remain poorly defined. Our data show for the first time that TUSC5 plays an important in vivo function in insulin-stimulated glucose uptake in adipose tissue by affecting proper GLUT4 recycling in response to a prolonged insulin stimulus. Furthermore, we demonstrate that in patients TUSC5 expression correlates with improved insulin sensitivity. Also, the insulin sensitizing effect of the thiazolidinedione (TZD) class of drugs seems to be mediated by TUSC5 to a certain degree.
Insulin-stimulated glucose clearance into adipose tissue ultimately depends on functional GLUT4, which relies on several additional broadly expressed proteins [13, 18, 19, 32, 37, 55] that predominantly co-localize to the same insulin-responsive vesicles as GLUT4 (GSVs) [21, 26, 56] . In contrast to other studied GSV proteins, which are expressed in similar vesicle trafficking systems in other tissues [1,21,24e26 ,57], we show that TUSC5 is the first tissue-specific insulin-responsive protein involved in this process. Based on our data, it is plausible that TUSC5 enables GLUT4 function by utilizing this more ubiquitous system of proteins. This is in line with other tissue-specific proteins for which it has been estimated that roughly half of such proteins interact with more broadly expressed proteins to facilitate their function [58] . In this sense TUSC5 may differentiate insulinstimulated glucose uptake in adipose tissue and muscle. Based on our data, one could envision a scenario where TUSC5 boosts long-term GLUT4 recycling in adipose tissue, promoting glucose uptake beyond the 30 min post-ingestion peak observed in muscle [59] . Prolonged glucose uptake fits well with the role of adipose tissue as a long-term energy storage organ but more studies focusing on glucose uptake kinetics will be needed to confirm this hypothesis. Given the fact that Tusc5 expression was reported in primary somatosensory neurons [41] in humans a function for this protein in the regulation of vesicle formation, might be envisaged as well. Based upon our findings, we hypothesize that TUSC5 ensures the intracellular protein associations that are crucial to the formation of functional GLUT4 vesicles during protein recycling by facilitating proteineprotein interactions. TUSC5 co-precipitants are strongly enriched for proteins widely recognized as markers for the recycling endosome and retrograde trafficking including the transferrin receptor [21, 27] and the syntaxin 6, syntaxin 16, VAMP3 and Vti1A SNARE bundle [17, 60, 61] . Moreover, TUSC5 ablation led to disrupted protein distribution during prolonged insulin stimulation, a time frame in which protein recycling is strongly engaged [28, 31, 55] . This recycling pathway is distinct from, or potentially upstream of, traditional GSV biogenesis from the TGN, a process thought to be driven largely by sortilin [22, 37, 62, 63] . As we hypothesize TUSC5 is functional mainly during insulin-stimulated recycling, our model does not completely preclude the formation of functional GSVs from the TGN (e.g. after protein synthesis or once insulin stimulation is completely removed). In this way, TUSC5 ablation does not halt vesicle formation during protein recycling entirely, but rather impedes correct proteineprotein associations. This results in the formation of incomplete vesicles that are depleted of key functional proteins (e.g. VAMP2, VAMP3 and IRAP) and drives the observed vesicle mislocalization and blunted membrane fusion. In fact, specific depletion of these same proteins that show a reduced association with GLUT4 when TUSC5 is ablated (i.e. IRAP and VAMP2/3) recapitulates key elements of our observed TUSC5 knockdown phenotype, including reduced glucose uptake [64, 65] and aberrant GLUT4 localization [66, 67] . Tusc5 knockout mice on a high-fat diet exhibit a reduced ability to clear post-prandial glucose but the phenotype observed here is mild when compared to tissue-specific GLUT4 models [4, 5] . Interestingly, global Glut4 knockout mice also exhibit a rather mild metabolic phenotype, a discrepancy attributed to compensatory up-regulation of other glucose transporter protein levels [68] , although no such compensation could be detected in Tusc5 knockout mouse adipose tissue. A key difference between these models and ours is that TUSC5 ablation leaves an abundance of GLUT4 that may retain a degree of function via undisturbed trafficking (i.e. exocytosis from TGN-sourced GSVs), a process that TUSC5 ablation does not preclude. It will be important to investigate the degree to which this trafficking route exists in Tusc5 knockout mice and can compensate for disrupted recycling. Many pharmaceutical treatments (i.e. TZDs) improve insulin sensitivity in type 2 diabetics by selectively agonizing the nuclear transcription factor PPARg [69] . However, the mechanism of action of these drugs is incompletely understood. Our data confirm TUSC5 as a PPARg target in vitro and in vivo and further demonstrate, in accordance with previous work, that the insulin sensitizing effect of rosiglitazone is mediated in part by through TUSC5 [57] . A past study found no increase in Tusc5 mRNA in pioglitazone-treated patients. However, due to the small cohort size, it remains unclear whether Tusc5 is regulated in response to TZDs in patients. Our finding is particularly interesting as it may open new avenues for the treatment of type 2 diabetes with potentially less pronounced side effects, especially if TUSC5 levels or function can be manipulated pharmaceutically. Further, our patient data support the importance of TUSC5 in the face of obesity as two cohorts show that TUSC5 levels are predictive of improved insulin sensitivity. This finding may provide an explanation as to why a sub-set of individuals manage to stave off insulin resistance and type 2 diabetes despite chronic obesity [70, 71] .
In conclusion, our present study identifies TUSC5 as a novel regulator of prolonged insulin stimulated GLUT4 trafficking, thereby regulating glucose uptake in adipocytes. Furthermore, our studies qualify TUSC5 as a unique insulin-responsive protein conferring tissue specificity to the GLUT4 translocation machinery via the promotion of proper protein recycling. As glucose disposal via GLUT4 is integral to the maintenance of insulin sensitivity and the prevention of diabetes during obesity, TUSC5 may be critical in the progression of this disease [4, 5] . Given the fact that TUSC5 regulates vesicle fusion and recycling it is at the moment difficult to envisage how this protein could be targeted to improve glucose homeostasis. Future studies on TUSC5 may bring a deeper understanding of GLUT4 and its role in the maintenance of glucose homeostasis in obesity.
